Which has higher earnings and valuation, GERN or ALKS?

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 4.36 -$83.50M -$0.11 N/A Alkermes $1.48B 4.76 $241.66M $0.90 46.88

Is GERN or ALKS more profitable?

Alkermes has a net margin of 9.78% compared to Geron's net margin of -35.48%. Alkermes' return on equity of 9.26% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Geron -35.48% -23.31% -10.08% Alkermes 9.78% 9.26% 5.66%

Does the media favor GERN or ALKS?

In the previous week, Alkermes had 4 more articles in the media than Geron. MarketBeat recorded 6 mentions for Alkermes and 2 mentions for Geron. Alkermes' average media sentiment score of 1.29 beat Geron's score of 1.16 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GERN or CLDX?

In the previous week, Geron and Geron both had 2 articles in the media. Celldex Therapeutics' average media sentiment score of 1.31 beat Geron's score of 1.16 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GERN or BCRX?

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Geron. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 2 mentions for Geron. Geron's average media sentiment score of 1.16 beat BioCryst Pharmaceuticals' score of 0.91 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, INVA or GERN?

Innoviva has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.84 $271.17M $6.01 3.56 Geron $183.88M 4.36 -$83.50M -$0.11 N/A

Is INVA or GERN more profitable?

Innoviva has a net margin of 119.89% compared to Geron's net margin of -35.48%. Innoviva's return on equity of 33.33% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% Geron -35.48% -23.31% -10.08%

Does the media refer more to INVA or GERN?

In the previous week, Innoviva had 2 more articles in the media than Geron. MarketBeat recorded 4 mentions for Innoviva and 2 mentions for Geron. Geron's average media sentiment score of 1.16 beat Innoviva's score of 0.58 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NVAX or GERN?

Novavax has higher revenue and earnings than Geron. Novavax is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.61 $440.30M -$0.58 N/A Geron $183.88M 4.36 -$83.50M -$0.11 N/A

Is NVAX or GERN more profitable?

Novavax has a net margin of -14.73% compared to Geron's net margin of -35.48%. Novavax's return on equity of -14.82% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Geron -35.48% -23.31% -10.08%

Does the media refer more to NVAX or GERN?

In the previous week, Novavax had 14 more articles in the media than Geron. MarketBeat recorded 16 mentions for Novavax and 2 mentions for Geron. Geron's average media sentiment score of 1.16 beat Novavax's score of 0.70 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Geron (GERN) Competitors

$1.25 0.00 (0.00%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$1.26 +0.01 (+0.80%)

As of 04:44 AM Eastern

Compare

GERN vs. ALKS, CLDX, BCRX, INVA, and NVAX

Should you buy Geron stock or one of its competitors? MarketBeat compares Geron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Geron include Alkermes (ALKS), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does Geron compare to Alkermes?

Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Alkermes had 4 more articles in the media than Geron. MarketBeat recorded 6 mentions for Alkermes and 2 mentions for Geron. Alkermes' average media sentiment score of 1.29 beat Geron's score of 1.16 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Geron presently has a consensus price target of $2.50, indicating a potential upside of 100.00%. Alkermes has a consensus price target of $45.40, indicating a potential upside of 7.61%. Given Geron's higher probable upside, equities research analysts plainly believe Geron is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.36	-$83.50M	-$0.11	N/A
Alkermes	$1.48B	4.76	$241.66M	$0.90	46.88

Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Alkermes has a net margin of 9.78% compared to Geron's net margin of -35.48%. Alkermes' return on equity of 9.26% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Alkermes	9.78%	9.26%	5.66%

Summary

Alkermes beats Geron on 15 of the 17 factors compared between the two stocks.

How does Geron compare to Celldex Therapeutics?

Geron (NASDAQ:GERN) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

73.7% of Geron shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Geron has higher revenue and earnings than Celldex Therapeutics. Geron is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.36	-$83.50M	-$0.11	N/A
Celldex Therapeutics	$1.54M	1,601.91	-$258.76M	-$4.26	N/A

Celldex Therapeutics has a net margin of 0.00% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Geron has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Geron currently has a consensus target price of $2.50, indicating a potential upside of 100.00%. Celldex Therapeutics has a consensus target price of $49.78, indicating a potential upside of 58.38%. Given Geron's higher probable upside, research analysts plainly believe Geron is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Geron and Geron both had 2 articles in the media. Celldex Therapeutics' average media sentiment score of 1.31 beat Geron's score of 1.16 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celldex Therapeutics beats Geron on 9 of the 16 factors compared between the two stocks.

How does Geron compare to BioCryst Pharmaceuticals?

Geron (NASDAQ:GERN) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Geron presently has a consensus price target of $2.50, indicating a potential upside of 100.00%. BioCryst Pharmaceuticals has a consensus price target of $20.70, indicating a potential upside of 132.32%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

73.7% of Geron shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Geron. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 2 mentions for Geron. Geron's average media sentiment score of 1.16 beat BioCryst Pharmaceuticals' score of 0.91 indicating that Geron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a net margin of -35.48% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Geron's return on equity of -23.31% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

BioCryst Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.36	-$83.50M	-$0.11	N/A
BioCryst Pharmaceuticals	$874.84M	2.59	$263.86M	-$1.78	N/A

Geron has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Summary

BioCryst Pharmaceuticals beats Geron on 10 of the 16 factors compared between the two stocks.

How does Geron compare to Innoviva?

Innoviva (NASDAQ:INVA) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Innoviva had 2 more articles in the media than Geron. MarketBeat recorded 4 mentions for Innoviva and 2 mentions for Geron. Geron's average media sentiment score of 1.16 beat Innoviva's score of 0.58 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva presently has a consensus target price of $36.20, indicating a potential upside of 69.00%. Geron has a consensus target price of $2.50, indicating a potential upside of 100.00%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Innoviva has a net margin of 119.89% compared to Geron's net margin of -35.48%. Innoviva's return on equity of 33.33% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Geron	-35.48%	-23.31%	-10.08%

Innoviva has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Innoviva has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.84	$271.17M	$6.01	3.56
Geron	$183.88M	4.36	-$83.50M	-$0.11	N/A

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 1.7% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Innoviva beats Geron on 12 of the 16 factors compared between the two stocks.

How does Geron compare to Novavax?

Novavax (NASDAQ:NVAX) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Novavax had 14 more articles in the media than Geron. MarketBeat recorded 16 mentions for Novavax and 2 mentions for Geron. Geron's average media sentiment score of 1.16 beat Novavax's score of 0.70 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has higher revenue and earnings than Geron. Novavax is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.61	$440.30M	-$0.58	N/A
Geron	$183.88M	4.36	-$83.50M	-$0.11	N/A

Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, Geron has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Novavax has a net margin of -14.73% compared to Geron's net margin of -35.48%. Novavax's return on equity of -14.82% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Geron	-35.48%	-23.31%	-10.08%

Novavax currently has a consensus price target of $12.13, indicating a potential upside of 10.53%. Geron has a consensus price target of $2.50, indicating a potential upside of 100.00%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

53.0% of Novavax shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Novavax beats Geron on 9 of the 16 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GERN vs. The Competition

Export

Metric	Geron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$801.90M	$3.40B	$6.40B	$12.57B
Dividend Yield	N/A	2.29%	2.68%	5.31%
P/E Ratio	-11.36	18.88	21.37	26.27
Price / Sales	4.36	334.85	559.83	114.93
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	3.57	6.93	10.08	6.86
Net Income	-$83.50M	$24.20M	$3.56B	$337.26M
7 Day Performance	-2.34%	4.02%	2.86%	3.53%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	-19.09%	65.97%	37.63%	39.66%

Geron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GERN Geron	2.8589 of 5 stars	$1.25 flat	$2.50 +100.0%	-19.1%	$801.90M	$183.88M	N/A	70	Positive News
ALKS Alkermes	2.6293 of 5 stars	$36.95 -0.1%	$45.40 +22.9%	+36.8%	$6.16B	$1.56B	41.06	2,050	Positive News Gap Down
CLDX Celldex Therapeutics	2.4504 of 5 stars	$30.58 -1.0%	$49.78 +62.8%	+61.3%	$2.43B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	3.1168 of 5 stars	$8.37 -4.2%	$20.70 +147.3%	-17.0%	$2.22B	$874.84M	N/A	530
INVA Innoviva	3.59 of 5 stars	$22.20 -0.2%	$36.20 +63.1%	+9.1%	$1.64B	$411.33M	3.69	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GERN) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Geron (GERN) Competitors